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a  b  s  t  r  a  c  t
A  double-blind,  randomized  controlled  trial was  conducted  in an endemic  focus  for  Schistosoma  man-
soni  in  Kafr  El-Sheikh  Governorate,  Northern  Nile  Delta,  Egypt,  to evaluate  the  prophylactic  effect  of
artemether  (ART) given  in  conjunction  with  praziquantel  (PZQ).  The  study  encompassed  913  primary
school  children  randomly  assigned  to  two treatment  groups  PZQ/ART  and  PZQ/ART-placebo.  At base-
line,  both  groups  received  40  mg/kg  body  weight  of  PZQ  twice  four weeks  apart,  after  which  one group
received  6 mg/kg  body  weight  of ART  every  3 weeks  in  5 cycles  during  the  transmission  season  and  the
other  group  received  ART-placebo.  At the  end of the  study,  prevalence  of  infection  among  the  PZQ/ART
was  approximately  half that  of the  PZQ/ART-placebo  group,  i.e.  6.7%  versus  11.6%, and  incidence  of  new
infections  for the  PZQ/ART  was  2.7%  versus  6.5%  for the PZQ/ART-placebo.  In conclusion,  PZQ/ART  com-
bined  therapy  might  be  considered  as an  adjunct  measure  against  human  schistosomiasis,  by  speciﬁcallyeywords:
chistosoma mansoni
andomized control trial
raziquantel
rtemether
rophylaxis
reducing  transmission  and  therefore  contribute  to disease  elimination.
© 2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).gypt
. IntroductionSchistosomiasis is a neglected tropical disease (NTD) that
emains one of the most prevalent parasitic infections in the humid
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nstitute; RHU, Rural Health Units; CI, conﬁdence interval; ACTs, artemisinin-based
ombination therapies.
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/).tropics ranking second only after malaria in terms of gravity and
public health importance (Chitsulo et al., 2000). The estimated
global burden of the three most common schistosome species,
Schistosoma mansoni, Schistosoma haematobium and Schistosoma
japonicum has been reported to be 4–5 million disability-adjusted
life years (DALYs) (World Health Organization, 2002) but would be
considerably higher if subtle morbidities were included. The great
majority of the world’s burden of schistosomiasis is concentrated in
the African continent with an overall estimated average prevalence
of approximately 10% (Steinmann et al., 2006; Utzinger et al., 2009).
In Egypt, both S. mansoni and S. haematobium species are endemic.
Currently, the number of infections due to S. mansoni exceeds that
of S. haematobium due to ecological changes inﬂuenced by the shift
in irrigation system from basin to perennial following the construc-
tion of the Aswan High Dam (Dazo and Biles, 1972; Malek, 1975).
In Egyptian hyper-endemic foci of S. mansoni infection, the preva-
lence even approaches 70% and the percentage of heavily infected
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ndividuals, i.e. those excreting more than 400 eggs per gram (EPG)
f faeces accounts for 20% of those infected (Barakat et al., 2000).
The World Health Organization (WHO) recommends schistoso-
iasis control through large-scale mass drug administration (MDA)
ith PZQ, a key anti-morbidity strategy that remains in place to
ate (World Health Organization, 1983, 2011). Chemotherapy as a
easure of control is feasible and sustainable if distributed repeat-
dly according to deﬁned, long-term schedules (World Health
rganization, 2011). The Egyptian Ministry of Health and Popu-
ation (MOHP) has implemented a large-scale control programme
ince the early 1980s supported by international agencies including
he United Nations Development Program (UNDP) and the United
tates Agency for International Development (USAID). The outcome
as excellent during the ﬁrst implementation phase with preva-
ence rates falling throughout the country (Barakat et al., 2014).
owever, shortly after cessation of control measures, infection
ndices increased drastically exceeding baseline levels. In addition,
ew infection foci appeared in areas claimed to have been secure
Talaat et al., 1999; El-Khoby et al., 2000; Barakat, 2013; Abdel-
ahab et al., 2000). It was also noticed that the age pattern had
hifted in the direction of more infections among children and
ccurring at a younger age (Barakat et al., 1998).
In the late 1990s, the MOHP followed up with more vigorous
ontrol strategies based on MDA  and providing chemotherapy to all
ndividuals in hyper-endemic foci annually regardless of infection
tatus. However, transmission continued unabated as snail control
ad been abandoned and PZQ does not affect the immature stages of
he parasite leaving new infections to mature and start egg produc-
ion (World Health Organization, 2011; Cioli and Pica-Mattoccia,
003; Pica-Mattoccia and Cioli, 2004). Although snail control mea-
ures affect disease transmission, application is not always feasible
ue to the high cost of molluscicides and their broad-spectrum
ffect on the fauna, e.g. ﬁsh, as well as administrative and logis-
ic limitations of its use, particularly as preventive chemotherapy
s now the recommended main approach (Taylor, 2008).
Artemether (ART), a methyl-ether derivative of dihy-
roartemisinin (Li and Wu,  2003), in addition to its excellent
nti-malarial properties, also exhibits activity against the imma-
ure stages of Schistosoma spp. (Shuhua et al., 2000; Utzinger
t al., 2001, 2000; Utzinger and Keiser, 2004; Xiao et al., 2002;
ergquist et al., 2004; N’Goran et al., 2003). The administration of
 dose of 6 mg/kg once every 2–4 weeks, reduces the incidence of
chistosome infection signiﬁcantly (Utzinger et al., 2001; Utzinger
nd Keiser, 2004). Peak efﬁcacy of the drug varies from two weeks
fter cercarial skin penetration for S. japonicum to four weeks for
. haematobium.  ART complements PZQ as its effect is focused
n the juvenile stage, thereby blocking the development of new
dult stages (Shuhua et al., 2000; Utzinger et al., 2001; Utzinger
nd Keiser, 2004; Xiao et al., 2002). Theoretically, combined drug
herapy should completely wipe out schistosome infection in the
uman host as there would be no replacement of the adult worms
y those maturing, as is the case after exclusive PZQ treatment.
his type of combined treatment should ultimately impact trans-
ission by reducing overall egg excretion from the human host.
t is worth noting that ART treatment might also have an effect
omparable to a vaccine as shown in a previous experimental
tudy, where ART treatment in the second and third week after
nfection resulted in immune responses that protected mice at the
evel of 58% and 81% respectively (Bergquist et al., 2004).
After initial Chinese trials of artemisinin derivatives for pre-
ention of S. japonicum infection (unpublished in the international
iterature), several clinical trials have conﬁrmed the effect of ART
gainst the three most common species (Utzinger et al., 2000;
’Goran et al., 2003; Li et al., 2005). A comprehensive meta-analysis
rom 2011, refers to 52 trials and 38 articles on the antischistosomal
fﬁcacy of different medication strategies with various artemisininpica 158 (2016) 52–58 53
derivatives including combination therapy with PZQ (Liu et al.,
2011). According to this systematic review, it is preferable to use
complementary treatment regimen which includes PZQ and mul-
tiple doses of ART or artesunate (Liu et al., 2011). Given these facts
and since ﬁeld studies evaluating the ART effect on Egyptian Schis-
tosoma species do not exist so far, we  set the following objectives:
1. Evaluate the prophylactic effect of ART chemotherapy on schis-
tosomiasis mansoni in a double-blind randomized controlled
trial.
2. Assess the safety and efﬁcacy of combined PZQ and ART versus
PZQ only.
2. Methods
2.1. Ethical approval and ﬁnancial support
The study protocol was approved by the Ethical Review Board,
Ministry of Health and Population (MOHP), Egypt. Before the imple-
mentation of the study, written informed consents were obtained
from the guardians of the children. The study was funded by the
Special Programme for Research and Training in Tropical Diseases
(TDR) (ID No.: SGS02/39).
2.2. Study area
The study was conducted in a hyper-endemic area for S. mansoni
in the north-western region of the Metobas District, Kafr El-Sheikh
Governorate (KES), which is located in the northern part of the Nile
Delta (Fig. 1). It is bordered by the Mediterranean Sea to the north,
the Rosetta Nile Branch to the west, the Dakahleya Governorate
to the east, and the Gharbeya Governorate to the south. One of
the main geographical features of the coastal area of KES is the El-
Borolos Lake which is located in the northern part of the Nile Delta
and connected to the Mediterranean Sea by the Boghase-El-Borolos
canal. The whole study area is free from malaria.
2.3. Study design and study sample
A randomized, double blind controlled trial was conducted dur-
ing the period 2003–2005. The study encompassed a total of 913
primary school children attending grades 1–5, aged 6–11 years. The
children were randomized into two treatment groups using a com-
puter generated random list. The PZQ/ART-placebo group included
453 children, and the combined-therapy group (PZQ/ART) included
460 children. Both the investigators and the study participants were
blinded as to which participants were given ART or ART-placebo.
Considering an attrition rate of 10%, the sample size was estimated
to give the study at least 80% power at 0.05 level of signiﬁcance to
detect the difference between the two  treatment groups.
2.4. Socio-demographic data
The data form contained the following personal information:
name, class, identiﬁcation number, gender, residence, body weight,
compliance to stool sample collection and treatment and results of
stool sample analysis. The investigators dealing with the data were
unaware about the group identity of the study subjects until the
ﬁnal analysis of data at the end of the study.
2.5. Stool sample evaluationSince the most intense schistosomiasis transmission in Egypt is
from April through October, the study was started in the former
month, when stool samples were collected to determine baseline
prevalence and intensity of infection. For the assessment of PZQ
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Fig. 1. Kafr El Sheikh Governorate showing the lo
Table 1
Project activities by date for both treatment and control groups from April 2003 to
October 2003.
Dates and tasks performed Treatment group
PZQ/ART
Control group
PZQ/ART-placebo
Collection of the1st stool sample April 13–14
√ √
PZQ  Mass treatment—1st dose of PZQ April
15–16
√ √
2nd  stool sample taken for cure assessment
May  11–12
√ √
PZQ  Mass treatment—2nd dose of PZQ May
14–15
√ √
1st  dose of ART/placebo May  25–26
√ √
2nd  dose of ART/placebo June 15–16
√ √
3rd  dose of ART/placebo July 6–7
√ √
4th  dose of ART/placebo July 27–28
√ √
√ √
c
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a5th  dose of Art/placebo August 17–18
Stool sample for end-of-intervention
assessment October 24–25
√ √
ure rate, a second stool sample was collected four weeks after the
rst dose of PZQ. At the end of the study in October, stool samples
ere again collected to evaluate the impact of treatment regimens
mong the two groups (Table 1). Because schistosomiasis con-
rol in Egypt resulted in a substantial, relatively long-term effect,
trongly downregulating indices of infection (Barakat et al., 2014), it
s justiﬁable, more feasible and cost-effective to implement control
ctivities every two years. Therefore, stool samples were recol-
ected approximately two  years following the latest intervention
o evaluate the long-term effect of the combined-chemotherapy
egimen.
All stool samples were processed according to Katz et al. (1972):
wo slides each of 43.7 mg  faeces were prepared from each sample
nd examined microscopically by well-trained parasitology techni-cation of the study area (Metobas District).
cians (Swiss TPH, April 2005). Egg counts from the two slides were
averaged and the EPG of stool was computed. The outcome was
used to calculate the geometric mean EPG of stool (GMEC). All EPG
values were transformed into log10 +1 to allow for zero counts, and
the GMEC was  computed as the anti-log10 of the mean of the log10
egg counts.
Validity and reliability of parasitological data were assured by
re-examination of 10% of the slides, which were randomly selected.
Slides were re-checked by a senior parasitologist if the
re-examination data were not strongly correlated with the origi-
nal data. In addition, any slide with only one egg was  also rechecked
by an experienced parasitologist.
2.6. Chemotherapy
After estimating the baseline prevalence of infection and regard-
less of the infection status, PZQ (donated free-of-charge by the
MOHP) was given to all participants in a dose of 40 mg/kg of
body weight according to the MOHP policy for hyper-endemic
foci (World Health Organization, 2011). Since PZQ is only effec-
tive against the adult stage of the parasite, a second dose of the
drug was  administered four weeks after the ﬁrst dose and couple
of days after the collection of the second stool sample. Administra-
tion of PZQ in two doses ensures that almost every participant was
free of infection before the start of ART therapy.
ART and ART-placebo, were donated by Kunming Pharmaceuti-
cal Industries through the Swiss Tropical and Public Health Institute
(Swiss TPH). ART treatment was repeated every three weeks dur-
ing the transmission season from May  to August. The drug was
administered in a single oral dose, each of 6 mg/kg of body weight.
The PZQ/ART-placebo group followed the same schedule, but here
ART-placebo was administered to the participants (Table 1). Poten-
H. Elmorshedy et al. / Acta Tro
Table  2
Treatment and stool compliance rates.
Compliance to ART Compliance to stool
ART dose N % N %
1st 430 100.0 859 94.1
2nd  423 98.4 854 93.5
3rd  422 98.1
t
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5th 403 93.7 855 93.6
ial adverse effects of the drugs were assessed immediately and
fter 24 h in all participants of the two treatment groups (PZQ/ART
nd PZQ/ART-placebo). During the school summer vacation, the
hildren were reached through house visits, which necessitated
ommunity participation in the form of regular meetings with com-
unity leaders, doctors at Rural Health Units (RHU) and parents.
n addition, mass campaigns were conducted during the Friday
rayers at local mosques to motivate parents to adhere to the treat-
ents scheduled for their children.
.7. Statistical analysis
Data were analyzed using SPSS, version 16.0 (IBM, New York,
Y, USA). Comparisons, presented as percent difference of S. man-
oni infections between PZQ/ART and PZQ/ART-placebo recipients
ere subjected to Pearson’s Chi-square test (Kirkwood and Sterne,
003). GMEC values were computed for the positive cases with 95%
onﬁdence interval (CI). The unpaired t-test was used for compari-
on of the two treatment groups using log-transformed egg counts,
ecause the distribution of intensity of infection, as measured by
PG following treatment is right-skewed, i.e. in the majority of
ases, there are only a few or no parasites left after treatment,
hile a few individuals showed relatively large parasite burdens,
 tendency best described by considering their geometric mean
Kirkwood and Sterne, 2003). All tests were two-sided and the 0.05
evel was used as the cut-off value for statistical signiﬁcance.
. Results
.1. Study sample and compliance rates
Overall, a total of 2568 stool samples were collected during the
hole study period resulting in a compliance rate of 93.8%. The
ates during the various collection occasions were the following:
t the baseline in April, 859 (94.1%) samples were collected and in
ay, 854 (93.5%) samples were collected four weeks following PZQ
hemotherapy for cure assessment. At the end of the study, follow-
ng the peak of transmission season in October 2003, 855 (93.6%)
tool samples were collected. As for chemotherapy compliance, 853
hildren (93.4%) received the two doses of PZQ at the baseline.
mong children in the PZQ/ART group, 403 (93.7%) received the
 scheduled doses of the drug (Table 2).
.2. Baseline parasitological data
At baseline, there was no signiﬁcant statistical difference
etween the indices of infection among the two treatment groups:
revalence rates were 30.2% and 27.3%, and the corresponding
MECs values were 59.8 and 57.6 EPG for the PZQ/ART and the
ZQ/ART-placebo, respectively. Following PZQ chemotherapy, the
verall cure rate was 83.2%. The difference in cure rate between the
wo treatment groups was not signiﬁcant, being 79.5% and 87.2%
or the PZQ/ART and the PZQ/ART-placebo respectively. The GMEC
f uncured cases was comparable among the two  treatment groupspica 158 (2016) 52–58 55
with no statistically signiﬁcant difference. All these data are sum-
marized in Table 3.
3.3. Impact of chemotherapy
On whole, shortly after treatment, few children complained of
mild side effects as nausea and abdominal pain, while no side effects
of medical importance were recorded among the two  treatment
groups. The S. mansoni prevalence rate for the combined treatment
regimen in the PZQ/ART group was  signiﬁcantly lower than that
of the PZQ/ART-placebo. The overall prevalence was  6.7% for the
PZQ/ART group compared to 11.6% for the PZQ/ART-placebo group.
Accordingly, the reduction in prevalence for the combined therapy
group was signiﬁcantly higher than that for the PZQ/ART-placebo,
i.e. 77.8% versus 57.5%. The impact of ART on the incidence of infec-
tion was  evident, as it was  found to be 2.7% versus 6.5% for PZQ/ART
and the PZQ/ART-placebo, respectively. The relative risk of devel-
oping new infection was 0.42, 95% CI (0.19–0.950), P = 0.024, which
indicated that the incidence of infection among the ART/PZQ group
is 0.425 times as likely as in the PZQ/ART-placebo group (Table 4).
The longitudinal impact of chemotherapy intervention after two
years from base line revealed that the prevalence of infection was
comparable for the two treatment groups being 6.6% and 8.1% for
PZQ/ART and the PZQ/ART-placebo respectively (Table 5).
4. Discussion
The current key strategy to control schistosomiasis relies on PZQ
alone (World Health Organization, 1983, 2011). However, this drug
fails to prevent reinfection, so transmission continues at high lev-
els in many places (Barakat, 2013; Tchuem Tchuente et al., 2013).
Furthermore, reliance on a single drug may  ultimately lead to
the development of drug-resistant schistosome strains. Reduced
susceptibility to PZQ has already been documented under exper-
imental conditions and among humans as reported from Senegal,
Kenya and Egypt (Utzinger et al., 2009; Botros et al., 2005; Silva
et al., 2005; Doenhoff et al., 2008; Fallon et al., 1995). However,
substantial year-to-year variation in drug efﬁcacy is common, so
the patterns reported may  not be consistent with rapid, progres-
sive emergence of resistance to PZQ (King et al., 2000). Even so,
the risk cannot be ignored and the development of new ‘fall-back’
drugs remains a pressing need.
ART is not a novel discovery, as it has been used for malaria
therapy for a long time. However, the surprising ﬁnding is that
it is also effective against schistosomula of various schistosome
species (Utzinger and Keiser, 2004; Xiao et al., 2002; Utzinger
et al., 2000; N’Goran et al., 2003; Li et al., 2005) and thus con-
stitutes a novel application. Its effect on immature schistosome
stages complements PZQ that only acts against adult worms (Cioli
and Pica-Mattoccia, 2003). Drugs acting on different developmen-
tal stages of the parasite, such as PZQ and ART, improve cure rate,
reduce the risk of developing resistant strains and ultimately block
parasite transmission. Since the artemisin group of drugs is impor-
tant for malaria treatment, the emerging threat of artemisinin
resistance should not be ignored (Djimde et al., 2015), and the drug
should therefore not be used against schistosomiasis where there is
malaria transmission. However, combination therapy against schis-
tosomiasis would be possible in areas close to elimination of the
disease, such as North Africa and China where malaria is absent.
The results of our study show that compliance with respect
to the ﬁve scheduled doses of ART was 93.7%. Concordantly, in
an S. japonicum-endemic focus in China, the drug was  given 9–11
times consecutively with a compliance rate of 84.8% without any
adverse effects (Xiao, 2005; Wang, 2006). In our study, the extent
of ART impact on S. mansoni infection was  evident in the combined
56 H. Elmorshedy et al. / Acta Tropica 158 (2016) 52–58
Table  3
Matching of the two treatment groups according to the status of infection.
Treatment group Baseline GMEC of uncured cases Cure rate
Prevalence GMEC (95%CI) Number Positive GMEC (95% CI)
PZQ/ART 130/431 59.8 (47–76) 34 25 (19–34) 101/127
30.2% 79.5%
PZQ/ART-placebo 117/428 56.7 (44–76) 23 25 (18–35) 102/117
27.3% 87.2%
Test  of signiﬁcance X2 = 0.84 t = 0.84 t = 0.02 X2 = 2.55
P-value 0.360 0.360 0.983 0.110
Table 4
Impact of treatment on the indices of Schistosoma mansoni infection according to drug regimen.
Treatment group Results after 5 doses of ART (end of transmission season)
Prevalence % reduction* GMEC of positives (95% CI) % reduction in GMEC* Incidence
PZQ/ART 29/427 27 (18–41) 55.1% 8/299
6.8% 77.5% 2.7%
PZQ/ART-placebo 48/421 28 (21–38) 51.0 20/306
11.4% 58.2% 6.5%
Test  of signiﬁcance X2 = 5.46 t = 0.20 X2 = 5.11
P-value 0.019* 0.845 0.024** Relative risk (RR) (0.425),95% CI (0.19–0.95)
*Percent reduction from the baseline.
**<0.05 = signiﬁcant.
Table 5
Longitudinal impact of treatment on the percentage of Schistosoma mansoni infec-
tion according to drug regimen.
Treatment group Baseline After two  years
PZQ/ART No. 130/431 23/351
%  30.2 6.6
PZQ/ART-placebo No. 117/428 28/347
%  27.3 8.1
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ommended the use of ART whenever appropriate as an additionalSigniﬁcance test (X ) 0.84 0.59
P-value 0.360 0.441
reatment group showing a remarkably higher overall prevalence
eduction for ART recipients as compared to the PZQ/ART-placebo
roup. This can be explained by the effect of ART against immature
orms and translating into a protective effect against re-infection
ll through the transmission season. Experimental studies have
evealed that appropriately timed ART administration may  not only
ely on its direct effect on the infection status, but that the drug
lso exhibits an effect comparable to a vaccine by destruction of
he invading parasites at sites preferential for the generation of
rotective immunity (Bergquist et al., 2004).
As far as we know, this is the ﬁrst study to date in Egypt test-
ng the impact of ART on human schistosomiasis in a community
etting. In other countries, endemic for human schistosomiasis,
andomized controlled trials have shown that ART is effective
gainst the three common schistosome species (Utzinger et al.,
000; N’Goran et al., 2003; Li et al., 2005). Results from a sys-
ematic review reveal that PZQ and ART in combination result in
 higher protection rate [in general, up to 84%, (95% CI: 64–91%)]
han PZQ monotherapy for treatment of human schistosomiasis
Wang, 2006). In accordance with these results, an ART ﬁeld trial
n Côte d’Ivoire showed that S. mansoni infection was  50% lower
n the children who received 6 doses of ART three weeks apart
ompared to placebo (Utzinger et al., 2000), while Chinese stud-
es have shown even higher protection rates—one as high as 96%
95% CI: 78–99%) (Liu et al., 2011), and another, carried out in a
yper-endemic focus following the transmission season, where the
revalence was reduced by 92.9% and the intensity of infection was
educed by 96.1% among ART recipients (Li et al., 2005). The dif-
erence between the aforementioned studies and the present one
ould be attributed to strain differences, differences in study designas well as to differences in the indices of infection. In the present
study, only 5 doses of ART were used, while between 9 and 11 doses
were given in the Chinese study (Xiao, 2005; Wang, 2006). In addi-
tion, in the Chinese study, the intensity of infection was  calculated
for all participants regardless of their infection status, i.e. nega-
tive results were included in the calculation of the mean intensity
of infection, leading to an overestimation of the impact of ART. In
comparison, the GMEC was  only calculated for the positive subjects
in the present study.
After the transmission season, at the end of the follow-up, both
treatment groups showed remarkable GMEC reductions. However
the difference between the two treatment groups was  not statis-
tically signiﬁcant. This can be explained by the ongoing annual
chemotherapy control programmes adopted by the MOHP leading
to modulation of the immune response of the target population.
In the Côte d’Ivoire study, GMEC was signiﬁcantly lower in the
ART group than in the placebo ones (Utzinger et al., 2000). How-
ever, participants in this study were not subjected to repeated PZQ
chemotherapy and no control campaigns had been launched in the
area before the start of the study. In addition, children received 6
doses of ART compared to 5 doses in the present study. Other causes,
such as genetic variations of schistosome strains and differences in
the seasons where the two  studies were conducted, might also have
been contributing factors.
The impact of the drug on immature infections can be assumed
by the difference in incidence rates between the two treatment
groups. In our study, the incidence among the ART/PZQ recipients
was less than half that of the PZQ/ART-placebo group. The superior
effect of ART on the incidence of new infection has been shown pre-
viously (Utzinger et al., 2000; N’Goran et al., 2003; Li et al., 2005).
In Côte d’Ivoire, incidence of S. haematobium in the ART/PZQ group
was 49% compared to 65% for the PZQ-only group and the protec-
tive efﬁcacy was 0.25, (95% CI: 0.08–0.38, P = 0.007) (N’Goran et al.,
2003). In the same region, the incidence of S. mansoni was  24% for
the group that received ART compared to 49% among the placebo
group and the relative risk was 0.5, (95% CI 0.35–0.71, P = 0.00006)
(Utzinger et al., 2000). The authors of the Côte d’Ivoire studies rec-tool for the control of schistosomiasis (N’Goran et al., 2003).
In this study, the longitudinal effect of the combined therapy
after two  years from the intervention demonstrated that preva-
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ence in the group that received PZQ/ART was slightly lower than
hat among those received PZQ/ART-placebo. Although the differ-
nce was not statistically signiﬁcant, this might indicate the need
o schedule treatment repeats on annual basis in high and mod-
rate risk areas. Accordingly, further investigations are needed to
arefully determine the schedule of treatment repeats as tailored
o the level of disease endemicity.
Finally, it is worth mentioning that the study design did not
nclude a group receiving PZQ only at every time point that would
nequivocally have shown if there indeed would be a difference
etween the two drugs regimens investigated. However, had only
ZQ been used, re-infections would not have been cured until the
orms reached maturity, while ART would have ‘nipped them in
he bud’ as it were, making sure that no egg-laying worms would
ppear at all, thus giving this drug the edge. Another fact that speaks
n favour of combination therapy, is that neither drug alone has a
00% efﬁcacy. By attacking the parasite with two drugs with differ-
nt killing mechanisms should augment the efﬁcacy of each drug.
lthough the available data are not sufﬁcient to settle whether this
rgument holds, drugs acting on different developmental stages of
he parasite should improve cure rates, reduce the risk for drug
esistance and ultimately contribute to blocking transmission.
In conclusion, ART is a safe drug that has shown a clear pro-
hylactic effect against Schistosoma species through its action on
he immature stages. The PZQ/ART combination demonstrated a
ynergistic effect on prevalence and intensity of infection. The
rug should be considered an additional tool for efﬁcacious control
f human schistosomiasis in areas where malaria is not endemic
nd/or in situations where disease elimination is envisioned.
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